Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-03-08
2005-03-08
Leith, Patricia (Department: 1654)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094100, C424S094610, C424S094630, C424S094640, C424S094670, C424S601000, C526S123100, C514S912000
Reexamination Certificate
active
06863886
ABSTRACT:
An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.
REFERENCES:
patent: 3728223 (1973-04-01), Kaneko et al.
patent: 3869548 (1975-03-01), Dabis
patent: 3945889 (1976-03-01), Mima et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4174389 (1979-11-01), Cope
patent: 4258134 (1981-03-01), Yoshida et al.
patent: 4474751 (1984-10-01), Haslam et al.
patent: 4490351 (1984-12-01), Clark, Jr.
patent: 4757089 (1988-07-01), Epstein
patent: 4820516 (1989-04-01), Sawyer et al.
patent: 4861760 (1989-08-01), Mazuel et al.
patent: 4871742 (1989-10-01), Bonne et al.
patent: 4897349 (1990-01-01), Swann et al.
patent: 4904594 (1990-02-01), Karlstam
patent: 5061627 (1991-10-01), Olsen et al.
patent: 5077033 (1991-12-01), Viegas et al.
patent: 5166331 (1992-11-01), Della Valle et al.
patent: 5252318 (1993-10-01), Joshi et al.
patent: 5260059 (1993-11-01), Acott et al.
patent: 5270051 (1993-12-01), Harris
patent: 5292509 (1994-03-01), Hageman
patent: 5300295 (1994-04-01), Viegas et al.
patent: 5316926 (1994-05-01), Brown et al.
patent: 5318780 (1994-06-01), Viegas et al.
patent: 5326761 (1994-07-01), Rozier
patent: 5366964 (1994-11-01), Lindstrom et al.
patent: 5496726 (1996-03-01), Park et al.
patent: 5593877 (1997-01-01), King
patent: 5747027 (1998-05-01), Stern et al.
patent: 5756552 (1998-05-01), Takeuchi et al.
patent: 5827721 (1998-10-01), Stern et al.
patent: 5866120 (1999-02-01), Karageozian et al.
patent: 6039943 (2000-03-01), Karageozian et al.
patent: 6123938 (2000-09-01), Stern et al.
patent: RE37336 (2001-08-01), Weigel et al.
patent: 6551590 (2003-04-01), Karageozian et al.
patent: 6610292 (2003-08-01), Karageozian et al.
patent: 0 193 330 (1986-09-01), None
patent: 0625579 (1994-11-01), None
patent: 0892045 (1999-01-01), None
patent: 1048725 (2000-11-01), None
patent: WO 9718835 (1997-05-01), None
patent: WO 0077221 (2000-12-01), None
Anloszyk, et al., “An Experimental Model of Preretinal Neovascularization in the Rabbit” Investigative Ophthalmology & Visual Science, 32 : 46-52 (1991).
Belkin, et al., “Urokinase-Treatment of Fresh Laser Irradiation-Induced Vitreous Hemorrhage”, Ophthalmologica, Basel, 187 : 152-156 (1983).
Benson, et al. (1971)Vitreous Hemorrhage. Survey of Ophthalmology 5:297-311.
Biozyme Laboratories web page: http://www.biozyme.com/p38.html.
Boyer, et al. (1958)Studies on Simulated Vitreous Hemorrhages. A.M.A. Archives of Ophthalmology 59:333-338.
Borowski, et al. “Influence of Hyaluronidaze on Vitreous Haemorrhages”, Klin. Oczna 87: 129-30 (1985).
Bramsen, T., “The Effect of Urokinase on Central Corneal Thickness and Vitreous Haemorrhage”, Acta Ophthalmologica, 56 1006-1012 (1978).
Calbiochem 1994/95, CATALOG 1994/95 (6 pages).
Chapman-Smith, et al., “Urokinase in the Management of Vitreous Haemorrhage”, British Journal of Ophthalmology, 61 : 500-505 (1977).
Cleary,e t al., “Intravitreal Urokinase in the Treatment of Vitreous Hemorrhage”, Transactions of the Ophthalmological Societies of the United Kingdom, 94 : 587-590 (1974).
Coleman, et al., “The Role of Vitrectomy in Traumatic Vitreopathy”, Symposium: Pars Plana Vitrectomy, 81 :OP 406-OP413, (1976).
Coles, et al., “Vitrectomy in Intraocular Trauma”, Archives ofOphthamology, 87 : 621-628 (1972).
Constable, et al., “Pathology of Vitreous Membranes and the Effect of Hemmorrhage and New Vessels on the Vitreous”, Transactions of the Ophthalmological Societies of the United Kingdom, 95 : 382-388 (1975).
Dugmore, et al., “Intravitreal Urokinase in the Treatment of Vitreous Hemmorrhage”, American Journal of Ophthalmology, 75 : 779-781 (1973).
Singh, Daljit, (1995) “Subconjunctival Hyaluronidase Injection Producing Temporary Myopia,”Journal of Cateract&Refractive Surgery, vol. 21, pp. 477-478.
Yee et al., (1994) “Treatment With Streptokinase in Experimental Penetrating Keratoplasty in Rabbits,”Investigative Ophthalmology&Visual Science, vol. 35, p. 1878.
“Enzyme Nomenclature-Enzyme List”, International Union of Biochemistry and Molecular Biology, prepared for NC-IUBMB by Edwin C. Webb, pp. 350, (1992).
Forrester, et al., “Resolutions of Intravitreal Clots by Urokinase”, LANCET, 2 : 179 (1973b).
Forrester, et al., “Lytic Therapy in Vitreous Hemorrhage”, Transactions of the Ophthalmological Societies of the United Kingdom, 94 : 582-588 (1974).
Forrester, et al., “Total Vitreous Haemorrhage A Method of Treatment, ”Transactions of the Ophthmological Societies of the United Kingdom, 94 : 992-999 (1974).
Forrester, et al., “Intravitreal Fibrinolysis on Experimental Vitreous Hemorrhage”, Experimental Eye Research, 22 : 181-188 (1976).
Forrester, et al., “The Effect of Fibrinolytic Inhibition in the Resolution of Experimental Vitreous Haemorrhage”, American Journal of Ophthalmology, 84 : 810-814 (1977).
Forrester, et al., “The Pathology of Vitreous Hemorrhage. I Gross and Histological Appearances”, Archives of Ophthalmology, 90 : 703-710 (1978).
Forrester, et al., “The Pathology of Vitreous Hemorrhage, II. Ultrastructure”, Archives of Ophthalmology, 57 : 2368-2374 (1979).
Foulds, et al., Effect of Intravitreal Hyalruondise on the Clearance of Triliated Water from the Vitreous to the Choroid British Journal of Ophthalmology, 69 : 529-532 (1985).
Ghartey, et al., “Closed Vitreous Surgery, XVII. Results and Complications of Pars Plana Vitrectomy”, Archives of Ophthalmology, 98 : 1248-1252 (1980).
Gibbons, et al., “Retinal Damage from Suprathreshold Q-switch Laser Exposure”, Health Physics, 35 : 461-469 (1978).
Gottlieb, et al., “The Safety of Intravitreal Hyaluronidase”, Investigative Ophthalmology Visual Science, 31 :2345-2352 (1990).
Greer, et al., “A Study of Stimulated Vitreous Hemorrahge Using Labeled Blood”, Archives of Ophthalmology, 79 : 755-758 (1968).
Hageman, et al., “Chrondroitin 6-Sulfate Glycosaminoglycan is a Major Constituent of Primate Cone Photoreceptor Matrix Sheaths”, Dept. of Anatomy and Cell Biology, Univ. of Southern California School of Medicine, Los Angeles, Current Eye Research, 6 : 639-646 (1987).
Harooni, et al. (1998)Efficacy and Safety of Enzymatic Posterior Vitreous Detachment by Intravitreal Injection of Hyaluronidase. Retina 18:116-22.
Harooni, et al. (1996)Efficacy and Safety of Vitreous Liquefaction by Intravitreal Injection of Hyaluronidase. Abstract: Investigative Ophthalmology and Visual Science, Annual Meeting Fort Lauderdale, FL. Apr. 21, through Apr. 26, 1996.
Holmes,e t al., “Intravitreal Urokinase in the Management of Vitreous Haemorrhage”, Transcript of Ophthalmological Societies of the United Kingdom, 94 : 591-596 (1974).
Kang, et al. (1995)Induction of Bitreolysis and Vitreous Detachment with Hyaluronidase and Perfluoroproopane Gas. Korean J. Ophthalmol. 9:69-78.
Karageozian, et al., “Hyaluronidase in intravireal use; evaluation of toxicity in animal model”, Investigative Opthmalmology & Visual Science, 38(4), abstract XP002076958, (May 15, 1997).
Kim, et al., “The Influence of Enzymes and Inflammation on Absorption of Experimentally Induced Vitreous Hemorrhage”, Dept. of Ophthalmology, Korea Univ. Medical Journal, 9(1) : 87-97 (1972).
Knepper, et al. (1984)Exogenous Hyaluronidases and Degradation of Hyaluronic Acid in the Rabbit Eye. Investigative Opht
Aragon Gabriel Arturo Carpio
Flores Jose L. G.
Karageozian Hampar
Karageozian Vicken
Kenney Maria C.
Advanced Corneal Systems
Knobbe Martens Olson & Bear LLP
Leith Patricia
LandOfFree
Use of hyaluronidase in the manufacture of an ophthalmic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hyaluronidase in the manufacture of an ophthalmic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hyaluronidase in the manufacture of an ophthalmic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3409956